Aytu BioPharma Reports Record Revenue from ADHD Asset
Aytu Biopharma (Nasdaq: AYTU) has announced its financial and operational results for the fiscal 2024 second quarter. The company’s ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 49% to $16.6 million, compared to $11.1 million in the prior year period.
Josh Disbrow, Chairman and Chief Executive Officer of Aytu, commented, “Our ADHD Portfolio experienced a 49% year over year increase in net revenue during the second quarter to an Aytu record of $16.6 million driven by strong sales force execution and an enhanced commercial approach, along with continuing to leverage our innovative Aytu RxConnect platform, which we believe is a best-in-class patient support program.”
Highlights
Aytu’s consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company’s Consumer Health Segment.
Net revenue from the company’s Rx Segment was $18.7 million compared to $18.0 million in the prior year period.
Consolidated operating income during Q2 2024 was $2.4 million compared to an operating loss of $6.9 million in the prior year period.
Net loss during Q2 2024 was $0.2 million, or $0.04 per share, compared to a net loss of $6.7 million, or $2.15 per share, in Q2 2023.
Consolidated adjusted EBITDA was $5.1 million in Q2 2024 compared to $0.7 million in the prior year period, a 599% increase.
The company had a cash balance of $19.5 million at December 31, 2023.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
